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Abstract: Premature ejaculation (PE) is a common problem in men worldwide. It has a 
signiﬁ  cant impact on affected men and their partners in terms of self-esteem, dissatisfaction 
with their sexual relationships, personal distress, and interpersonal difﬁ  culty. Psychological 
therapies may achieve short-term improvements, but there are limited data on the long-term 
success of these methods. Oral therapy with long-acting selective serotonin reuptake inhibitors 
(SSRIs) improves intravaginal ejaculatory latency time (IELT), but these agents are designed to 
be administered daily and may be associated with unwanted sexual side effects and withdrawal 
symptoms upon abrupt discontinuation. Dapoxetine is a short-acting SSRI that can be taken 
as needed (prn) by men with PE. It has been studied in ﬁ  ve separate multicenter, randomized, 
double-blind, placebo-controlled trials involving more than 6000 men with PE. In four studies that 
evaluated IELT as an endpoint (N = 4843), dapoxetine 30 and 60 mg prn achieved statistically 
signiﬁ  cant increases in IELT versus placebo. Dapoxetine also showed statistically signiﬁ  cant 
improvements in perceived control over ejaculation, PE-related personal distress, and other 
patient-reported outcomes in all ﬁ  ve trials. Dapoxetine treatment is generally well-tolerated, 
with low incidences of discontinuation syndrome, sexual dysfunction, and treatment-emergent 
mood symptoms. The most common adverse events with dapoxetine included nausea, diarrhea, 
headache, dizziness, and somnolence.
Keywords: dapoxetine, discontinuation syndrome, premature ejaculation, selective serotonin 
reuptake inhibitor
Introduction
Premature ejaculation (PE) is the most common form of male sexual dysfunction.1 
Globally, between 20% and 40% of men, at some point in their lives, have reported 
symptoms of PE or a complaint of PE,1–3 which may be classiﬁ  ed as lifelong or 
acquired.4 Lifelong PE is characterized by early ejaculation in the majority of 
intercourse attempts with nearly every partner from the ﬁ  rst sexual encounter onwards, 
whereas acquired PE develops at some point in a man’s life after he has previously 
experienced normal ejaculation and may be linked to urological or psychological 
problems.4 Some have also suggested that 2 additional forms of PE be considered, 
including natural-variable PE and premature-like ejaculatory dysfunction. Natural-
variable PE is characterized by early ejaculations that occur sporadically and should 
be regarded as a normal variation in sexual performance.4 Premature-like ejaculatory 
dysfunction is characterized by a false perception of PE even though these men have 
normal to very long ejaculation times.4
In clinical practice and for the purposes of clinical trials, the most commonly used 
deﬁ  nition of PE has been the Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition, text revision (DSM-IV-TR), deﬁ  nition, which describes PE as “persistent 
or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after 
penetration and before the person wishes it” that “causes marked distress or interpersonal Neuropsychiatric Disease and Treatment 2009:5 38
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difﬁ  culty” and “is not due exclusively to the direct effects 
of a substance.”5 More recently, the International Society 
for Sexual Medicine (ISSM) has more precisely deﬁ  ned 
lifelong PE as “a male sexual dysfunction characterized by 
ejaculation which always or nearly always occurs prior to or 
within about 1 minute of vaginal penetration; the inability 
to delay ejaculation on all or nearly all vaginal penetrations; 
and negative personal consequences, such as distress, bother, 
frustration and/or the avoidance of sexual intimacy.”6
The negative impact of PE on both the man and his 
female partner can be signiﬁ  cant. The man may often feel 
ashamed and embarrassed at not being able to satisfy his 
partner; subsequently, low self-esteem, anxiety, and feelings of 
inferiority are common.7–10 Satisfaction with sexual intercourse 
and the sexual relationship may be reduced while personal 
distress and interpersonal difﬁ  culty may be increased in men 
with PE.8,10–12 Overall, many aspects of quality of life, including 
social functioning and emotional well-being, are signiﬁ  cantly 
decreased.10 In two surveys of the female partners of men 
with PE, sexual satisfaction was “poor” or “very poor” in 
approximately 25% of respondents, personal distress related to 
PE was reported as at least “moderate” by approximately 50% of 
respondents, and interpersonal difﬁ  culty was at least “moderate” 
in up to 32% of respondents.11,13 The level of personal distress, 
perceived lack of control over ejaculation, satisfaction with 
sexual intercourse, and degree of interpersonal difﬁ  culty is 
comparable for men with PE and their female partners.12
Despite the high prevalence of PE, very few men seek 
treatment.14,15 In the Premature Ejaculation Prevalence and 
Attitudes (PEPA) survey of more than 12,000 men, only 9% 
of men with self-reported PE sought help from a physician.2 
Factors discouraging men from seeking treatment included 
doubts regarding the effectiveness of medication, concerns 
about becoming reliant on medication to perform sexually, and 
discomfort or embarrassment in discussing their PE. Of the men 
who had sought treatment for their PE, 92% reported little or no 
improvement in their condition. Further, physicians rarely inquire 
about sexual health. In a separate international survey of 27,500 
men and women aged 40 to 80 years, only 9% of respondents 
said they had been asked about their sexual health at routine 
visits within the previous 3 years, but more than 40% felt this 
should have occurred.15 These ﬁ  ndings emphasize the need for 
an effective, well-tolerated, and acceptable treatment for PE.
The physiology of ejaculation 
and the role of serotonin
Ejaculation is a biphasic process consisting of emission, 
which involves the secretion of seminal fluid from the 
prostate and seminal vesicle, contraction of the smooth 
muscles of the seminal tract, and deposition of the sperm 
into the posterior urethra; and expulsion, which occurs when 
the semen is forced through the urethral meatus.16–18 Control 
mechanisms responsible for the inhibition of ejaculation 
descend from the supraspinal level and involve a number 
of regulatory neurotransmitters, the most widely studied 
of which is 5-hydroxytryptamine (5-HT), or serotonin. At 
least 3 serotonin receptor subtypes have been identiﬁ  ed 
as having a role in ejaculation, including 5-HT1a, 5-HT1b, 
and 5HT2c. Although activation of the 5-HT1a receptor 
exhibits proejaculatory effects, activation of the 5-HT1b and 
5-HT2c receptors are involved in the process of delaying 
ejaculation.16,17 It has been hypothesized that altered levels of 
serotonin or serotonin receptor sensitivity in the ejaculatory 
modulating centers of the central nervous system are the 
pathophysiologic basis of ejaculatory disorders.17
Current treatments for PE
Historically, PE was considered a psychosomatic problem.19,20 
Therefore, behavioral, cognitive, and sex/relationship 
therapies have been a key component of PE management. 
Behavioral approaches have generally focused on the 
physical aspect of PE, including the “squeeze” technique 
as ﬁ  rst described by Masters and Johnson in 197021 and 
the “stop-start” method described by Semans in 1956.22 
These involve engaging in sexual foreplay until just before 
the point of ejaculation and then either squeezing the head 
of the penis or stopping sexual activity until the urge to 
ejaculate subsides, at which point sexual activity may be 
resumed and the techniques repeated as necessary. Cognitive 
or sex therapy focuses on perceptions and feelings, improving 
communication between partners, increasing sexual skills 
and self-conﬁ  dence, and reducing anxiety associated with 
sexual activity.19 Short-term improvement with these 
behavioral approaches has been observed; however, there 
are limited data concerning the efﬁ  cacy of these methods in 
the long term.23–26
A number of pharmacologic therapies have been 
employed in the management of PE. Topical therapies for PE 
act by desensitizing the penis and do not alter the sensation 
of ejaculation.27 A topical cream containing local anesthetics 
lidocaine and prilocaine was effective in prolonging mean 
intravaginal ejaculatory latency time (IELT) by 6 to 8 minutes 
(vs 1–2 minutes with placebo; p   0.05), but this must be 
applied at least 20 minutes (no longer than 45 minutes) prior 
to sexual contact.28,29 A novel aerosol formulation of lidocaine 
and prilocaine has also shown signiﬁ  cant increases in IELT Neuropsychiatric Disease and Treatment 2009:5 39
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versus placebo (2.4- and 8-fold increases in two separate 
studies).30,31 Korean researchers have developed a topical 
cream (SS-cream) from natural products, which has local 
anesthetic properties and is applied to the penis 1 hour 
before sexual contact.27 In two randomized, double-blind, 
clinical trials, SS-cream (20-g dose) achieved a mean IELT 
of approximately 11 minutes, compared with 2.5 minutes 
for placebo.32,33
Such topical products can be applied on an as-needed 
(prn) basis and may be associated with fewer unwanted 
systemic adverse effects than oral therapies. However, side 
effects of these treatments may include loss of erection in 
men, a mild burning sensation within the vagina of the female 
partner, and numbness of the genitals in both partners.27,28,31 
In addition, topical treatments can be messy and inconvenient 
to use because they must be applied and wiped off at speciﬁ  c 
times before sexual contact.
Selective serotonin reuptake inhibitors (SSRIs), 
commonly used in the treatment of depression, are often 
used to treat PE, based on the observation that delayed 
ejaculation is a frequent side effect of this drug class. In one 
prospective study (N = 344) of patients being treated with 
SSRIs for psychiatric disorders, the incidence of delayed 
ejaculation ranged from 46% to 59%.34 In another study 
(N = 1022), the incidence of delayed ejaculation ranged 
from 50% to 64%.35 In both studies, paroxetine therapy was 
associated with the highest frequency of delayed ejaculation. 
In a third study of depressed patients (N = 203), the incidence 
of abnormal ejaculation following paroxetine treatment was 
24%, compared with 12% for ﬂ  uoxetine treatment.36
Results from several studies have shown that long-
acting SSRIs signiﬁ  cantly prolong IELT in men with PE 
when administered with chronic daily dosing. For example, 
in a randomized, double-blind study (N = 60), men with 
PE (deﬁ  ned as an IELT of  1 minute) were randomized 
to receive 6 weeks of treatment with different long-acting 
SSRIs or placebo. Fluoxetine (20 mg/day), paroxetine 
(20 mg/day), and sertraline (50 mg/day) achieved statistically 
signiﬁ  cant increases in mean IELT from baseline versus 
placebo (range of increases, 1.5–7 minutes).37 In a separate, 
smaller study (N = 34, including 17 men and their female 
partners), treatment with paroxetine (20–40 mg/day) achieved 
a signiﬁ  cant increase in median IELT from 0.5 minutes at 
baseline to 10 minutes after 6 weeks of treatment, compared 
with no change from baseline in median IELT with 
placebo therapy (p = 0.002).38 Eight weeks of citalopram 
(20–60 mg/day) treatment in men with PE (N = 26) has also 
been shown to signiﬁ  cantly prolong IELT when compared 
with placebo (from 0.5 minutes at baseline to almost 5 minutes 
after 8 weeks; p   0.01).39 One analysis40 of two randomized, 
controlled, crossover studies (N = 26 and 42) compared IELT 
data among men who received paroxetine 20 mg 3 to 4 hours 
prior to sexual intercourse either alone or following initial 
daily treatment with paroxetine 10 mg. The results of this 
analysis found that IELT was signiﬁ  cantly longer among men 
who were initially treated with paroxetine 10 mg daily.
A key limitation of therapy for PE with currently available 
SSRIs is that in addition to delaying ejaculation, this class of 
drugs has been associated with a number of unwanted sexual 
side effects. Decreased libido (41%–64%, in men and women), 
anorgasmia (31%–53%, in men and women), and impotence/
erectile dysfunction (ED; 10%–41%) have been observed 
following treatment with ﬂ  uoxetine, paroxetine, ﬂ  uvoxamine, 
sertraline, and citalopram.34,35 In addition, use of SSRIs may 
be associated with clinically signiﬁ  cant effects on mood, 
such as reduced ability to cry, express feelings, or care about 
the feelings of others, in men with and without psychiatric 
conditions.41 Finally, abrupt cessation of SSRI therapy may also 
be associated with discontinuation syndrome, which includes 
a cluster of unpleasant physical and psychological symptoms 
including dizziness, nausea or vomiting, fatigue, headache, and 
unsteady gait.42 Discontinuation syndrome is considered to be 
more common with SSRIs that have shorter half-lives.
Other systemic treatments that have been evaluated for 
the management of PE include the phosphodiesterase-5 
(PDE-5) inhibitors, currently licensed for the treatment of 
ED. The potential mechanism of action of PDE-5 inhibitors 
in the treatment of PE is unclear, but current proposals 
include a central effect via the nitric oxide/cyclic guanosine 
monophosphate pathway; peripheral effects on smooth 
muscle in the vas deferens, seminal vesicles, prostate, and 
urethra; the potential induction of peripheral analgesia; and 
prolongation of the duration of erection.43 Despite the success 
of PDE-5 inhibitors in treating ED, there have been limited 
data to suggest that these agents are effective in men without 
ED. For example, a single-dose, home-use study in young, 
healthy men found that sildenaﬁ  l did not improve any aspect 
of erectile function or sexual performance in this population, 
although sildenaﬁ  l was associated with a reduction in post-
ejaculatory refractory time.44 A systematic review of clinical 
trials assessing sildenaﬁ  l, tadalaﬁ  l, and vardenaﬁ  l concluded 
that changes in IELT with these agents are variable and 
difﬁ  cult to interpret because of inconsistencies in study 
design.45 In an 8-week double-blind study, sildenaﬁ  l prn 
increased mean IELT, but not to a signiﬁ  cantly greater 
degree than placebo.46 Because of its mechanism of action, Neuropsychiatric Disease and Treatment 2009:5 40
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sildenafil may be associated with headache, flushing, 
dyspepsia, rhinitis, and visual disturbances in some subjects. 
The combination of an SSRI (paroxetine or ﬂ  uoxetine) 
and sildenaﬁ  l or tadalaﬁ  l may improve IELT signiﬁ  cantly 
more than the SSRI alone, but the incidence of side effects 
is increased relative to monotherapy with either of these 
agents.47–49 Treatment with PDE-5 inhibitors may be effective 
in men with comorbid ED and PE, and these two conditions 
commonly occur together.2,50 For example, McMahon and 
colleagues45 suggested that combination therapy may be 
particularly effective for men with comorbid PE and ED; 
however, further study is needed in this area.
The oral opioid analgesic tramadol has also been assessed 
as a treatment for PE. Although the potential mechanism of 
action of tramadol in PE is not well understood, it may relate 
to the antinociceptive effects associated with μ-opioid binding, 
which may decrease sensitivity, as well as the inhibition of 
norepinephrine and serotonin reuptake, which may delay 
ejaculation.51 Further investigation is needed to determine the 
precise effects of tramadol on 5HT1a and 5HT2c. Two small 
clinical studies have evaluated the efﬁ  cacy of tramadol in treating 
PE. In the ﬁ  rst study (N = 60), tramadol prn increased mean IELT 
from 1.2 minutes at baseline to 7.4 minutes at the end of 8 weeks, 
compared with a change from 1.1 to 2.0 minutes with placebo 
(p   0.0001). In addition, 98% of subjects reported that they felt 
tramadol therapy was associated with a signiﬁ  cant increase in 
their control over ejaculation.51 In the second study, an 8-week 
parallel-group study (N = 64),52 similar ﬁ  ndings were reported.
In clinical practice, many of these treatment modalities 
are used in various combinations (eg, behavioral therapy and 
topical treatments); however, these combinations have rarely 
been rigorously evaluated in controlled clinical studies.
Dapoxetine: an emerging 
pharmacologic treatment for PE
Presently, no pharmacologic agent is approved by any 
regulatory agency speciﬁ  cally for the treatment of PE, 
which may contribute to undertreatment of the condition. 
Dapoxetine is a novel short-acting SSRI under development 
for the treatment of PE. In preclinical models, dapoxetine has 
been statistically shown to signiﬁ  cantly inhibit ejaculatory 
expulsion reﬂ  exes, acting at a supraspinal level.53,54 Similar 
to other SSRIs, dapoxetine exerts its effects primarily 
through the inhibition of the serotonin reuptake transporter, 
with minimal inhibitory activity at the norepinephrine 
and dopamine reuptake transporters.55 However, unlike 
long-acting SSRIs, which are typically administered in 
a chronic (daily) fashion and may take days or weeks to 
reach steady-state plasma concentrations,56 dapoxetine is 
a short-acting SSRI, which may be better suited to the prn 
treatment of PE.57
Compared with other agents currently in development 
for the treatment of PE, including new topical and other oral 
agents, the dapoxetine clinical development program is in the 
very late stages, as ﬁ  ve phase III trials evaluating more than 
6,000 subjects have been completed (Table 1).
Table 1 Design of the phase III clinical studies evaluating dapoxetine in premature ejaculation
Country or region Study populationa Study duration  Study medication Outcome measures
United States56 (2 studies of identical 
design)
2614 12 weeks Dapoxetine 30 mg prn 
Dapoxetine 60 mg prn 
Placebo prn
IELT
Control over ejaculation 
Satisfaction with sexual 
intercourse
CGIC
Asia-Paciﬁ  c57 1067 12 weeks Dapoxetine 30 mg prn 
Dapoxetine 60 mg prn 
Placebo prn
IELT
PEP
CGIC
International58 1162 24 weeks + 1-week 
randomized withdrawal
Dapoxetine 30 mg prn 
Dapoxetine 60 mg prn 
Placebo prn
IELT
PEP
CGIC
DESS
North America (Canada and the 
United States)59
1238 9 weeks + 1-week 
randomized withdrawal
Double-dummy:
Dapoxetine 60 mg qd 
Dapoxetine 60 mg prn 
Placebo prn 
Placebo qd
PEP
CGIC
DESS
aAll studies were randomized, double-blind, parallel-group, placebo-controlled.
Abbreviations: prn, as needed; IELT, intravaginal ejaculatory latency time; CGIC, Clinical Global Impression of Change; PEP, Premature Ejaculation Proﬁ  le; DESS, Discontinuation-
Emergent Signs and Symptoms checklist; qd, once daily.Neuropsychiatric Disease and Treatment 2009:5 41
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Pharmacokinetic proﬁ  le of dapoxetine
Dapoxetine ((+)–(S)–N, N–dimethyl–(a)–[2–(1–
naphthalenyloxy)ethyl]–benzenemethanamine hydrochlo-
ride) is a water-soluble powder with a molecular weight of 
341.88 and a pKa of 8.6, which is charged at physiological 
pH58 and has a rapid pharmacokinetic proﬁ  le. Dapoxetine 
is rapidly absorbed; after administration of single doses 
of dapoxetine 30 and 60 mg in healthy male volunteers, 
peak plasma concentrations were observed 1.01 and 
1.27 hours after administration, respectively.57 Elimination 
of dapoxetine is also rapid: the initial half-lives of dapoxetine 
30 and 60 mg are 1.3 and 1.4 hours, respectively.57 At 24 hours 
after administration, plasma concentrations of dapoxetine 
were below 4% of the peak for both doses.57 Multiple 
dosing of dapoxetine 30 and 60 mg showed little change 
in this pharmacokinetic profile, with minimal apparent 
accumulation.57 This is in contrast to long-acting SSRIs. 
In 1 review of 5 SSRIs including ﬂ  uoxetine, paroxetine, 
ﬂ  uvoxamine, sertraline, and citalopram, half-lives were 
reported to range from 21 hours to 4 days.56 In addition, 
multiple dosing of long-acting SSRIs leads to signiﬁ  cant 
accumulation; for example, chronic administration of parox-
etine resulted in an 8-fold increase in plasma concentrations,59 
while sertraline was found to result in a 2-fold increase.60
Clinical trial program for dapoxetine
The clinical efﬁ  cacy and safety of dapoxetine in men with PE 
has been extensively investigated in ﬁ  ve separate phase III, 
randomized, double-blind, parallel-group, placebo-controlled 
clinical trials that enrolled more than 6000 subjects. All of 
these studies were similar in design. In all studies, men were 
18 years or older with a DSM-IV-TR diagnosis of PE and 
were in a stable, monogamous, heterosexual relationship for 
at least 6 months61–64; these trials were conducted prior to 
the introduction of the ISSM criteria for PE. Four of these 
studies also required an IELT of 2 minutes or less at baseline 
for enrollment.
Efﬁ  cacy measures across trials included IELT (included 
in four studies), the Premature Ejaculation Proﬁ  le (PEP; 
included in three studies), and subject Clinical Global 
Impression of Change (CGIC; included in all 5 studies). The 
PEP is a validated instrument comprising 4 items related to 
PE (perceived control over ejaculation, personal distress 
related to ejaculation, satisfaction with sexual intercourse, 
and interpersonal difﬁ  culty related to ejaculation), each 
measured on ﬁ  ve-point scales.11,65 The CGIC assesses change 
in overall condition, scored on a 7-point scale from −3 
(“much worse”) to 3 (“much better”).61 Additional outcome 
measures included the evaluation of sexual side effects and 
the potential of dapoxetine to cause anxiety, changes in 
mood or affect, or SSRI discontinuation syndrome following 
abrupt cessation. Anxiety-related symptoms were evaluated 
using the Hamilton Anxiety Scale (HAM-A), and mood- 
and affect-related symptoms were measured using the Beck 
Depression Inventory II (BDI-II) and the Montgomery-
Åsberg Depression Rating Scale (MADRS). Discontinuation 
syndrome was evaluated using the Discontinuation-Emergent 
Signs and Symptoms (DESS) checklist.
Clinical outcomes with dapoxetine
Intravaginal ejaculatory latency time
Across the four trials that evaluated IELT, dapoxetine 
signiﬁ  cantly improved IELT compared with baseline and 
placebo. In an integrated analysis of two US studies,61 
mean IELT at baseline was approximately 0.9 minutes 
in all treatment groups. At the Week 12 endpoint, this 
increased to 1.75 minutes in the placebo group, 2.78 minutes 
in the dapoxetine 30-mg group, and 3.32 minutes in the 
dapoxetine 60-mg group. Further results from this integrated 
analysis indicated that both doses of dapoxetine achieved 
signiﬁ  cantly greater increases in mean IELT compared 
with placebo (p   0.0001 for both) and that dapoxetine 
60 mg showed a signiﬁ  cantly greater increase in mean 
IELT than dapoxetine 30 mg (p = 0.0007). Similar ﬁ  ndings 
were observed in the subgroups of men with baseline IELT 
of less than 30 seconds (found in a post hoc analysis), less 
than 1 minute, or 1 to 2 minutes. The signiﬁ  cant differences 
between dapoxetine and placebo were evident from the 
ﬁ  rst dose and at all other time points (Weeks 4, 8, and 12). 
Based on CGIC data in this study,61 it was estimated that the 
minimum important change in IELT was about 1 minute, 
which was achieved by 22%, 47%, and 51% of men receiving 
placebo, dapoxetine 30 mg, and dapoxetine 60 mg, respec-
tively (p   0.0001 for dapoxetine vs placebo).
Similar ﬁ  ndings were obtained in a 24-week international 
study conducted in 22 countries, primarily in Europe and 
South America. Mean IELT was approximately 0.9 minutes 
at baseline for all groups. By Week 12, IELT was signiﬁ  cantly 
greater with dapoxetine 30 mg (3.2 minutes) and 60 mg 
(3.5 minutes) than with placebo (1.9 minutes; p   0.001 
for both); these results were maintained through the Week 
24 endpoint.63 In a 12-week Asia-Paciﬁ  c study, baseline 
mean IELT was approximately 1 minute in all treatment 
groups. At Week 12, the baseline mean IELT increased to 
2.4 minutes with placebo, 3.9 minutes with dapoxetine 30 mg, 
and 4.2 minutes with dapoxetine 60 mg. The difference Neuropsychiatric Disease and Treatment 2009:5 42
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between both doses of dapoxetine and placebo was statistically 
signiﬁ  cant (p   0.001 for both).62
Patient-reported outcomes
Across all trials of dapoxetine, all patient-reported measures 
of PE were signiﬁ  cantly improved compared with both 
baseline and placebo. In the integrated analysis of two US 
studies,61 the percentage of subjects reporting “good” or 
“very good” perceived control over ejaculation improved 
from less than 0.3% of subjects across groups at baseline to 
23.9% and 30.2% at 12 weeks with dapoxetine 30 and 60 mg, 
respectively (vs 8.7% with placebo; p   0.0001 for both). 
Similar ﬁ  ndings were observed for satisfaction with sexual 
intercourse. Although less than 21% of subjects reported 
“good” or “very good” at baseline, 38.7% and 46.5% reported 
this level of satisfaction at 12 weeks with dapoxetine 30 and 
60 mg, respectively (vs 24.6% with placebo; p   0.0001 for 
both). In addition, the proportion of subjects rating their PE 
as “slightly better,” “better,” or “much better” on the CGIC 
at 12 weeks was signiﬁ  cantly higher with both dapoxetine 
30 mg (58%) and 60 mg (67%) than with placebo (26%; 
p   0.0001 for both).
A North American trial64 conducted at multiple centers 
in Canada and the United States was designed primarily to 
evaluate the potential for SSRI withdrawal syndrome with 
prn and daily (qd) dosing regimens of dapoxetine 60 mg. The 
referenced study included a 9-week treatment phase followed 
by a 7-day withdrawal phase. Results from the treatment 
phase of this study focused on the dapoxetine 60-mg prn arm 
because dapoxetine is intended to be taken as needed. In this 
study, perceived control over ejaculation was rated as “good” 
or “very good” at baseline by no subjects in the placebo group 
and by only 0.2% of subjects in the dapoxetine 60-mg prn 
group; however, at the study’s end (Week 9) this increased to 
20.4% with placebo and 39.7% with dapoxetine 60 mg prn.64 
Satisfaction with sexual intercourse was rated as “good” or 
“very good” by 9.5% and 7.9% of subjects in the placebo and 
dapoxetine 60-mg prn groups, respectively, at baseline. At 
study end, 54.7% of subjects receiving dapoxetine 60 mg prn 
had achieved this status, compared with 34.0% of subjects 
receiving placebo. Although approximately 5% of men in 
both groups reported “not at all” or “a little bit” for the level 
of personal distress related to ejaculation at baseline, 54.3% 
of those in the dapoxetine 60-mg prn group reported this 
level of distress at study endpoint (vs 35.3% with placebo). 
Assessments of interpersonal difﬁ  culty related to ejaculation 
also improved greatly with dapoxetine. Although 43.0% and 
40.9% of men reported “not at all” or “a little bit” for the 
level of interpersonal difﬁ  culty at baseline, this improved to 
76.8% of subjects receiving dapoxetine by study endpoint 
(vs 64.2% with placebo). In addition, 41.3% of men in the 
dapoxetine 60-mg prn group rated their CGIC as “better” or 
“much better” compared with 20.8% of men in the placebo 
group (p   0.001).
Similar results were obtained in the international and 
Asia-Paciﬁ  c trials. Preliminary data from the international 
trial showed that PRO measures, including perceived control 
over ejaculation and personal distress related to ejaculation, 
were signiﬁ  cantly improved with dapoxetine 30 and 60 mg 
versus placebo at Weeks 12 and 24 (p  0.001 for all).63 In 
addition, the percentage of men rating their PE as “slightly 
better,” “better,” or “much better” was 57.7% and 72.4% 
with dapoxetine 30 and 60 mg, respectively, compared with 
32.0% with placebo (Figure 1).66 Preliminary results from the 
Asia-Paciﬁ  c trial also showed signiﬁ  cant improvements with 
dapoxetine compared with placebo for all PRO measures, 
including PEP items and CGIC.
Beneﬁ  ts of dapoxetine for the female partner
In addition to improving the condition in men with PE, the 
female partners of men treated with dapoxetine also reported 
considerable beneﬁ  ts. In the integrated analysis of two US 
trials,61 the proportion of partners whose satisfaction with 
sexual intercourse at baseline was “fair,” “good,” or “very 
good” was 53% to 58% across the treatment groups. At 
the end of the study, this proportion remained unchanged 
in the placebo arm, whereas in the dapoxetine 30- and 
60-mg groups, the proportion increased to 72% and 78%, 
respectively (p   0.0001 for both). Similar improvements 
were observed for the female partner’s perception of the 
man’s control over ejaculation.67
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In the international study, less than 5% of women across 
treatment groups reported their partner’s control over 
ejaculation as “good” or “very good” at baseline. At the end 
of the 24-week treatment period, however, this increased 
to 25.0% and 32.3% for women whose partners were 
randomized to dapoxetine 30 mg and 60 mg, respectively, 
compared with 14.4% of women whose partners were 
randomized to placebo (p   0.001 for both).68 Similarly, 
satisfaction with sexual intercourse was rated as “good” or 
“very good” by less than 16% of the partners at baseline. 
At study end, satisfaction with sexual intercourse increased 
signiﬁ  cantly in both the dapoxetine 30-mg (33.8%) and 
60-mg (39.1%) groups, compared with placebo (19.4%; 
p   0.001 for both).68 Similar improvements were observed 
for partner-rated personal distress and interpersonal difﬁ  culty 
related to ejaculation.68
Safety and tolerability with dapoxetine
In the ﬁ  ve phase III clinical trials, dapoxetine was generally 
well-tolerated and showed an acceptable safety proﬁ  le. For 
example, the overall incidence of adverse events (AEs) in the 
Asia-Paciﬁ  c study was 18% for placebo, 33% for dapoxetine 
30 mg, and 50% for dapoxetine 60 mg.69 In the international 
trial, the overall incidence of AEs was 38.4%, 56.2%, and 
68.1%, respectively.63 Across trials, AEs were generally mild 
to moderate in severity.
The AE proﬁ  le of dapoxetine exhibited some similarities 
with that reported for long-acting SSRIs, but also showed 
some important differences from these agents. The most 
frequently reported AEs following dapoxetine treatment, 
including nausea, diarrhea, headache, dizziness, and 
somnolence, are summarized in Table 2 for the integrated 
analysis of two US trials.61 These frequently-reported AEs 
occurred more often with dapoxetine 60 mg than with 
dapoxetine 30 mg. A similar AE proﬁ  le was observed in the 
international, North American, and Asia-Paciﬁ  c trials.63,64,69 
The incidence of severe or serious AEs was low ( 5% and 
 1% of subjects, respectively) across trials. Less than 10% 
of subjects per treatment group in each study discontinued 
because of AEs, the most common of which was nausea 
( 4% in any treatment group). Discontinuation because of 
AEs occurred more often with dapoxetine 60 mg than with 
dapoxetine 30 mg.61,63,64,69
The incidence of cardiovascular AEs in the US studies was 
low ( 3% of subjects), and mean blood pressure and heart 
rate were similar with dapoxetine and placebo treatment.61 
Syncope has been observed in the phase III trials. In the US 
studies, syncope was observed in 2 subjects receiving placebo, 
3 receiving dapoxetine 30 mg, and 2 receiving dapoxetine 
60 mg.61 Syncope was also experienced by 2 subjects receiv-
ing dapoxetine 60 mg prn in the North American study.64 
Syncope with dapoxetine appears to be vasovagal in nature 
and generally occurred following the ﬁ  rst dose. In the clinical 
trial program, once subjects were educated to stay hydrated 
and recognize prodromal symptoms, there were no additional 
syncope events.
Dapoxetine has been associated with a low incidence 
of sexual side effects. During the 12-week double-blind 
treatment period in the integrated analysis of the two US 
studies, sexual dysfunction (ED, abnormal ejaculation, 
decreased libido, abnormal sexual function) was reported 
in 1.9% of subjects receiving placebo, compared with 
4.5% of subjects receiving dapoxetine 30 mg and 5.4% of 
subjects receiving dapoxetine 60 mg.61 In addition, in the 
9-month open-label extension of these trials, during which 
all participants (n = 1774) received dapoxetine 60 mg, sexual 
side effects were reported by 2.6% of subjects.70 Similar 
low incidences of sexual AEs were reported for the 9-week 
treatment phase of the North American study (placebo: 
2.4%; dapoxetine 30 mg: 3.3%; dapoxetine 60 mg: 3.6%).71 
As discussed previously, these ﬁ  ndings are in contrast to 
the incidences of sexual dysfunction reported in clinical 
Table 2 Summary of the most frequently-reported treatment-emergent adverse events in the integrated analysis of 2 US phase III 
studies
Adverse event, % Placebo (n = 870)a Dapoxetine 30 mg (n = 874)a Dapoxetine 60 mg (n = 870)a
Nausea 1.9 8.7 20.1
Diarrhea 1.4 3.9 6.8
Headache 4.0 5.9 6.8
Dizziness 0.8 3.0 6.2
Somnolence 0.2 3.2 2.8
Serious adverse events 0.9 0.3 0.6
aTotal randomized in the 2 US trials.
Adapted from The Lancet, 368, Pryor JL, Althof SE, Steidle C, et al. Efﬁ  cacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two 
double-blind, randomised-controlled trials. 929–937, 2006,61 with permission from Elsevier.Neuropsychiatric Disease and Treatment 2009:5 44
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studies of chronic long-acting SSRI therapy (up to 60% of 
subjects).34,35
The potential for SSRI discontinuation syndrome following 
abrupt withdrawal of dapoxetine was speciﬁ  cally evaluated in 
the international and North American trials, which included 
a 1-week randomized withdrawal from dapoxetine therapy. 
Discontinuation syndrome was deﬁ  ned as an increase of 4 
points or more on the DESS checklist over the 7-day with-
drawal period.72 In the international study, the incidence of 
discontinuation syndrome was 3.0% for subjects continuing 
to receive dapoxetine 30 mg, 1.1% for those continuing on 
dapoxetine 60 mg, and 1.3% for those continuing on placebo. 
Of those subjects who switched from dapoxetine to placebo, 
no subjects previously taking dapoxetine 30 mg and 3.3% 
of those previously taking dapoxetine 60 mg met the criteria 
for discontinuation syndrome.72 In the North American study, 
upon withdrawal of dapoxetine 60-mg qd treatment, 6.1% of 
subjects experienced insomnia (vs 2.4% of those remaining 
on dapoxetine therapy) and 4.8% (vs 1.2% of those remain-
ing on dapoxetine therapy) experienced dizziness.72
The inﬂ  uence of dapoxetine on mood and affect, as 
measured by the BDI-II and the MADRS, was assessed 
during the initial 9-week double-blind treatment phase of 
the North American trial.71 Mean changes from baseline to 
study end for these rating scales were similar for dapoxetine 
30 mg and 60 mg and placebo (BDI-II: −1.4, −1.7, −1.2, 
respectively; MADRS: −0.1, −0.2, −0.1, respectively). The 
incidence of depression-related AEs was less than 1% in all 
treatment groups.
In the North American and international studies, treatment-
emergent anxiety was also assessed using the HAM-A. 
There were no signiﬁ  cant differences between dapoxetine 
and placebo in changes from baseline in mean HAM-A total 
scores or individual item scores in either study.71,72 In the 
North American trial, the incidence of anxiety-related AEs 
was less than 2.5% across treatment groups.71
Summary
Premature ejaculation is a common sexual complaint among 
men of all ages, and it has a signiﬁ  cant impact on men and 
their female partners. Current treatment options for PE have 
demonstrated limited long-term efﬁ  cacy and/or undesirable 
side effects and have generally not been evaluated in large 
well-controlled clinical trials for the treatment of PE. Several 
new treatment options are in development for the treatment 
of PE, including oral and topical therapies.
Dapoxetine, a short-acting SSRI, is the most rigorously 
evaluated new agent being developed for the treatment of 
PE. Dapoxetine has demonstrated efﬁ  cacy and safety in 
ﬁ  ve large, randomized, placebo-controlled phase III clinical 
trials. In addition to signiﬁ  cantly prolonging IELT, subjects 
receiving dapoxetine have reported improvements in all other 
measures of PE evaluated, including perceived control over 
ejaculation, satisfaction with sexual intercourse, personal 
distress related to PE, interpersonal difﬁ  culty related to PE, 
and overall impression of change in PE severity. Dapoxetine 
is generally well-tolerated, with the most common side effect 
being nausea; in contrast to long-acting SSRIs, the incidence 
of undesirable sexual side effects, treatment-emergent 
anxiety, and discontinuation syndrome was low.
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